| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | MIRIMUS, INC. | 760 PARKSIDE AVE STE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R43GM154496 | Creation of the Next Generation RNAi Therapeutics and an in vivo model for their study | 000 | 1 | NIH | 12/11/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $350,000 ) |
| | 2024 | 2024 | MIRIMUS, INC. | 760 PARKSIDE AVE STE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R43GM154496 | Creation of the Next Generation RNAi Therapeutics and an in vivo model for their study | 000 | 1 | NIH | 9/20/2024 | $350,000 |
| | 2024 | 2023 | MIRIMUS, INC. | 760 PARKSIDE AVE STE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R41CA278070 | Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer | 000 | 1 | NIH | 7/19/2024 | $0 |
| | 2024 | 2021 | MIRIMUS, INC. | 760 PARKSIDE AVE STE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R44OD026184 | CRISPR/Cas-mediated development of an RNAi rat model system | 000 | 3 | NIH | 1/22/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $397,916 ) |
| | 2023 | 2023 | MIRIMUS INC | 760 PARKSIDE AVE | BROOKLYN | NY | 11226-1785 | KINGS | USA | R41CA278070 | Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer | 000 | 1 | NIH | 5/10/2023 | $397,916 |
|
| Issue Date FY: 2021 ( Subtotal = $1,011,479 ) |
| | 2021 | 2021 | MIRIMUS, INC. | 760 PARKSIDE AVENUE SUITE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R44OD026184 | CRISPR/Cas-mediated development of an RNAi rat model system | 000 | 3 | NIH | 5/4/2021 | $1,011,479 |
|
| Issue Date FY: 2020 ( Subtotal = $1,020,397 ) |
| | 2020 | 2020 | MIRIMUS, INC. | 760 PARKSIDE AVENUE SUITE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R44OD026184 | CRISPR/Cas-mediated development of an RNAi rat model system | 000 | 2 | NIH | 5/7/2020 | $1,020,397 |
| | 2020 | 2018 | MIRIMUS, INC. | 760 PARKSIDE AVENUE SUITE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R43OD026184 | High efficiency platform for rapid RNAi rat model development | 000 | 1 | NIH | 12/21/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2018 | MIRIMUS, INC. | 760 PARKSIDE AVENUE SUITE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R44CA188154 | Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research | 000 | 3 | NIH | 7/30/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $986,097 ) |
| | 2018 | 2018 | MIRIMUS, INC. | 760 PARKSIDE AVENUE SUITE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R44CA188154 | Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research | 000 | 3 | NIH | 3/15/2018 | $751,587 |
| | 2018 | 2018 | MIRIMUS, INC. | 760 PARKSIDE AVENUE SUITE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R43OD026184 | High efficiency platform for rapid RNAi rat model development | 000 | 1 | NIH | 7/31/2018 | $234,510 |
| | 2018 | 2018 | MIRIMUS, INC. | 760 PARKSIDE AVENUE SUITE 206 | BROOKLYN | NY | 11226-1785 | KINGS | USA | R43OD026184 | High efficiency platform for rapid RNAi rat model development | 001 | 1 | NIH | 8/24/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $656,563 ) |
| | 2017 | 2017 | MIRIMUS, INC. | 500 SUNNYSIDE BLVD RM 177 | WOODBURY | NY | 11797-2924 | NASSAU | USA | R44CA188154 | Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research | 000 | 2 | NIH | 4/6/2017 | $656,563 |
|
| Issue Date FY: 2014 ( Subtotal = $189,010 ) |
| | 2014 | 2014 | MIRIMUS, INC. | 1 BUNGTOWN RD. | COLD SPRING HARBOR | NY | 11724-2209 | SUFFOLK | USA | R43CA188154 | RNA interference - genetically engineered mouse models(RNAi-GEMMs): a novel appro | 000 | 1 | NIH | 8/4/2014 | $189,010 |
|
|
